Market Research Future has starting late imparted another examination to its wide research portfolio, which is titled as “Retinal Vein Occlusion Market Research Report – Global Forecast till 2023” gives an all-around examination the measure of market size and advancement.
Market Highlights
Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein occlusion market offering a huge growth opportunity to the market players. Moreover, the growing number of patients affected with lymphoma and multiple myeloma is also fueling the growth of the global retinal vein occlusion market.
According to the Centers for Disease Control and Prevention, in 2014, around 47,135 people were diagnosed with leukemia and out of which 23,564 people died from the disease. According to the American Cancer Society, around 4% of all cancers in the United States is lymphoma, additionally, it is estimated that in 2018, about 74,680 people including both adults and children will be diagnosed with lymphoma and around 19,910 people will die from this. According to the American Cancer Society, the risk of acquiring multiple myeloma in the United States is 1 in 143 that is 0.7%, additionally, it is estimated that in 2018, around 30,770 new cases are likely to be diagnosed and the estimated death toll would be around 12,770.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5377
The Global Retinal Vein Occlusion Market is expected to grow at a CAGR of 11.2% during the forecast period 2017-2023.
Major Players in the Retinal Vein Occlusion Market:
Some of the key players in this market are Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers, GlaxoSmithKline Plc, IRIDEX Corporation, Novartis, Quantel Medical Inc, Topcon Medical Systems, Inc., ZEISS, Lumenis, Sanofi Aventis, Valeant Pharmaceuticals, Alimera Sciences, Fovea Pharmaceuticals SA, Icon Biosciences, Suzuken Co.Ltd, Genentech, Inc., Ranbaxy Pharmaceuticals, Johnson & Johnson Services, Inc, Teva Pharmaceutical, Pfizer Inc., Astrazeneca, Aerpio Therapeutics Inc, Annexin Pharmaceuticals AB and others.
Segmentation:
The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment, and end user. On the basis of the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion. On the basis of the condition, it is segmented into non-ischemic and ischemic. Based on the diagnosis, it is segmented into optical coherence tomography (OCT), fundoscopic examination, fluorescein angiography, and others. On the basis of treatment, it is segmented into antivascular endothelial growth factor, corticosteroid drugs, laser retinal photocoagulation, and others. On the basis of the end users, it is segmented into hospitals and clinics, research & academics centers, and others.
Retinal Vein Occlusion Market Regional Analysis:
The Americas, Europe, Asia Pacific, and the Middle East & Africa.
The Americas dominate the global retinal vein occlusion market owing to the increasing prevalence of eye diseases. Additionally, high healthcare spending, well-developed technology, and increasing geriatric population will fuel the growth of the market.
The Americas market for retinal vein occlusion is divided into North America and South America. North America holds the major share in the market whereas, South America is showing the fastest growth owing to the presence of a huge opportunity for the development of the market in the region.
The Europe retinal vein occlusion market comprises of Eastern Europe and Western Europe. Western Europe comprises of countries such as Germany, the U.K, France, Italy, and Spain. Europe accounts for the second largest market for the global retinal vein occlusion owing to increasing support from the government, the presence of huge geriatric population, and high healthcare spending. Also, many European countries are trying to encourage the manufacturers for research & development for the introduction of advanced devices. In addition to this, increasing awareness and development in the healthcare infrastructure has provided a push to the growth of the market.
Asia Pacific is the fastest growing market for the global retinal vascular or vein occlusion. Presence of huge patient population, rapid development in technology and presence of a huge opportunity for the development of the market drives the growth of Asia Pacific retinal vascular or vein occlusion market. Also, the government of this region is looking forward to avail better treatment options from developed nations in order to improve the quality of life of their citizens. Additionally, growing geriatric population is also fueling the growth of the market in this region.
On the other hand, the Middle East & Africa holds the least share but will be a fastest growing region in the forecast period. However, due to the presence of poor and slow developing countries, especially, in the African region, it may hold least market share.
TABLE OF CONTENTS
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
2.5 Market Structure
Browse Full Reports @ https://www.marketresearchfuture.com/reports/retinal-vein-occlusion-market-5377
3 Research Methodology
3.1.1 Primary Research Methodology
3.1.2 Secondary Research Methodology
3.1.3 Market Share Analysis
3.1.4 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing Prevalence of Diabetes and Atherosclerosis (Impact Weightage 40%)
4.2.2 Change in Lifestyle (Impact Weightage 35%)
4.2.3 Increasing Prevalence of Glaucoma, Lymphoma, and Multiple Myeloma (Impact Weightage 25%)
4.3 Restraints
4.3.1 Side Effect of Treatment (Impact Weightage 60%)
4.3.2 High Cost Of Treatment (Impact Weightage 40%)
5 Market Factor Analysis
…Continued!
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312